Guideline Risk equation | Derivation cohorts | Eligibility for statin therapy† | Predicted outcomes | |
---|---|---|---|---|
Baseline examination* | Age range | |||
2012 ESC1 | Europe10 | 19–80 | ≥5%(age ≤60) | Fatal ASCVD: |
SCORE | 1967–1986 | ≥10% (age 60–65) | CHD, stroke etc | |
2013 ACC/AHA3 | FHS: 194811 12 | FHS: 30–59 | ≥7.5% | ASCVD: |
Pooled Cohort | CARDIA: 198513 | CARDIA: 18–30 | (strong/class I) | non-fatal MI, fatal CHD, |
Equations (PCE) | ARIC: 198614 | ARIC: 35–74 | 5% to <7.5% | fatal and nonfatal stroke |
CHS: 198915 | CHS: ≥65 | (weak/class IIa) | ||
NCEP-ATP III8 9 | Framingham | 30–74 | 20% (∼unconditional) | Hard CHD: |
ATP III | 19718 | 10% (conditional) | non-fatal MI, fatal CHD | |
2014 NICE4 | UK: 199316 | 35–74 | ≥10% | Fatal and non-fatal CVD: |
QRISK2–2013 | (updated annually) | CHD (+angina), stroke, TIA |
*Year baseline examination started.
†Ten-year risk for the predicted outcomes.
ARIC, Atherosclerosis Risk In Communities study; ASCVD, atherosclerotic cardiovascular disease; CARDIA, Coronary Artery Risk Development in Young Adults Study; CHD, coronary heart disease; CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; MI, myocardial infarction; NCEP-ATP III, National Cholesterol Education Program—Adult Treatment Panel III; NICE, National Institute for Health and Care Excellence; SCORE, Systematic COronary Risk Evaluation; TIA, transient ischaemic attack.